Patents by Inventor Hana Golding
Hana Golding has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11478542Abstract: This invention provides immunogenic compositions comprising an immune stimulant and an respiratory syncytial virus (RSV) oligopeptide or an unglycosylated RSV polypeptide. The RSV oligopeptides are shown in SEQ ID NO: 3-33. The unglycosylated RSV polypeptide may consist essentially of the ectodomain of an RSV G protein, such as that shown in SEQ ID NO: 2 or the ectodomain of an RSV F protein such as the ectodomain of the F protein shown in SEQ ID NO: 39.Type: GrantFiled: July 16, 2020Date of Patent: October 25, 2022Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Surender Khurana, Hana Golding
-
Publication number: 20200345829Abstract: This invention provides immunogenic compositions comprising an immune stimulant and an respiratory syncytial virus (RSV) oligopeptide or an unglycosylated RSV polypeptide. The RSV oligopeptides are shown in SEQ ID NO: 3-33. The unglycosylated RSV polypeptide may consist essentially of the ectodomain of an RSV G protein, such as that shown in SEQ ID NO: 2 or the ectodomain of an RSV F protein such as the ectodomain of the F protein shown in SEQ ID NO: 39.Type: ApplicationFiled: July 16, 2020Publication date: November 5, 2020Applicant: The United States of America, as represented by the Secretary, Department of Health and Human ServicInventors: Surender Khurana, Hana Golding
-
Patent number: 10744193Abstract: This invention provides immunogenic compositions comprising an immune stimulant and an respiratory syncytial virus (RSV) oligopeptide or an unglycosylated RSV polypeptide. The RSV oligopeptides are shown in SEQ ID NO: 3-33. The unglycosylated RSV polypeptide may consist essentially of the ectodomain of an RSV G protein, such as that shown in SEQ ID NO: 2 or the ectodomain of an RSV F protein such as the ectodomain of the F protein shown in SEQ ID NO: 39.Type: GrantFiled: February 18, 2016Date of Patent: August 18, 2020Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Surender Khurana, Hana Golding
-
Patent number: 10377798Abstract: Compositions and methods useful for producing an immune response in a subject specific for the RSV G protein are described herein. The new methods and compositions described herein are made possible by the development of a new recombinant RSV G protein fragment, which has been engineered for in vitro production and is antigenically similar to the native RSV G protein. The recombinant RSV G protein fragment is capable of inducing the production of RSV G-specific antibodies when injected into a subject. These antibodies can recognize both RSV A and RSV B strains and inhibit infection of both viruses. Accordingly, the compositions and methods described herein may be useful in protecting subjects from RSV infection via immunization, raising antibodies specific for RSV, which can in turn be used to treat RSV infection.Type: GrantFiled: December 2, 2014Date of Patent: August 13, 2019Assignee: The United States of America, as rerpresented by the Secretary, Department of Health and Human ServicesInventors: Surender Khurana, Hana Golding
-
Publication number: 20180110850Abstract: This invention provides immunogenic compositions comprising an immune stimulant and an respiratory syncytial virus (RSV) oligopeptide or an unglycosylated RSV polypeptide. The RSV oligopeptides are shown in SEQ ID NO: 3-33. The unglycosylated RSV polypeptide may consist essentially of the ectodomain of an RSV G protein, such as that shown in SEQ ID NO: 2 or the ectodomain of an RSV F protein such as the ectodomain of the F protein shown in SEQ ID NO: 39.Type: ApplicationFiled: February 18, 2016Publication date: April 26, 2018Applicant: The United States of America, as Represented by the Secretary, Dept. of Health and Human ServiceInventors: Surender Khurana, Hana Golding
-
Patent number: 9896484Abstract: The present invention includes influenza Hemagglutinin protein fragments that fold properly when expressed in bacteria.Type: GrantFiled: October 19, 2015Date of Patent: February 20, 2018Assignee: The United States of America as represented by the Secretary of the Department of Health and Human ServicesInventors: Surender Khurana, Hana Golding
-
Publication number: 20160368949Abstract: The present invention includes influenza Hemagglutinin protein fragments that fold properly when expressed in bacteria.Type: ApplicationFiled: October 19, 2015Publication date: December 22, 2016Inventors: Hana Golding, Surender Khurana
-
Publication number: 20160304565Abstract: Compositions and methods useful for producing an immune response in a subject specific for the RSV G protein are described herein. The new methods and compositions described herein are made possible by the development of a new recombinant RSV G protein fragment, which has been engineered) for in vitro production and is antigenically similar to the native RSV G protein. The recombinant RSV G protein fragment is capable of inducing the production of RSV G-specific antibodies when injected into a subject. These antibodies can recognize both RSV A and RSV B strains and inhibit infection of both viruses. Accordingly, the compositions and methods described herein may be useful in protecting subjects from RSV infection via immunization, raising antibodies specific for RSV, which can in turn be used to treat RSV infection.Type: ApplicationFiled: December 2, 2014Publication date: October 20, 2016Inventors: Surender KHURANA, Hana GOLDING
-
Patent number: 9163068Abstract: The present invention includes influenza Hemagglutinin protein fragments that fold properly when expressed in bacteria.Type: GrantFiled: November 2, 2010Date of Patent: October 20, 2015Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services, National Institutes of Health, Office of Technology TransferInventors: Surender Khurana, Hana Golding
-
Patent number: 9121855Abstract: This invention concerns methods for detecting the presence of an anti-HIV-1 antibody in a biological sample, the method comprising conducting an immunoassay comprising: (a) contacting the biological sample with at least one epitope that is recognized by the anti-HIV-1 antibody, wherein the contacting being under conditions sufficient to permit the anti-HIV-1 antibody if present in the sample to bind to the epitope and form an epitope-anti-HIV-1 antibody complex; (b) contacting the formed epitope-anti-HIV-1 antibody complex with an anti-HIV-1 antibody binding molecule, the contacting being under conditions sufficient to permit the anti- HIV-1 antibody binding molecule to bind to anti-HIV-1 antibody of the formed epitope-anti-HIV-1 antibody complex and form an extended complex; and (c) determining the presence or concentration of the anti-HIV-1 antibody in the biological sample by determining the presence or concentration of the formed extended complex; the epitope being present on a peptide comprising SEQ ID NType: GrantFiled: December 23, 2010Date of Patent: September 1, 2015Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Hana Golding, Surender Khurana
-
Patent number: 8980546Abstract: This invention relates to compositions and methods for the detection of immunodeficiency virus infection, especially immunodeficiency virus-1 (HIV-I) infection. The invention particularly concerns compositions and methods that may be used in HIV vaccine recipients whose sera may contain vaccine-generated anti-HIV-1 antibodies.Type: GrantFiled: May 21, 2010Date of Patent: March 17, 2015Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Hana Golding, Surender Khurana
-
Patent number: 8778847Abstract: Peptides and polypeptides that elicit immunogenic responses in a mammal; especially neutralizing antibodies, against human and avian influenza strains H1N1, H3N2, H5N1 and H7N7 are disclosed Immunogenic compositions including these peptides, and polypeptides are also provided. Compositions including these peptides and polypeptides with or without adjuvants are disclosed. Nucleic acids and expression cassettes encoding these peptides and polypeptides are also disclosed. Methods of inhibiting infection by influenza, with or without cell entry, are also disclosed using these peptides and polypeptides.Type: GrantFiled: June 13, 2008Date of Patent: July 15, 2014Assignee: The United States of America, as represented by the Secretary of the Department of Health and Human ServicesInventors: Hana Golding, Surender Khurana
-
Patent number: 8722324Abstract: This invention relates to compositions and methods or the detection of human immunodeficiency virus-1 (HIV-1) infection by conducting an immunoassay comprising the steps of: (a) contacting a biological sample containing HIV-1 antibody with a peptide, having an epitope, of one or more of SEQ ID 49-56 to form a peptide-anti-HIV-1 antibody complex; (b) contacting the formed complex with an anti-HIV-1 antibody binding molecule to permit the anti-HIV-1 antibody binding molecule to bind to the anti-HIV-1 antibody of the formed peptide-anti-HIV-1 antibody complex and form an extended complex that is immobilized on a solid support; (c) removing unbound anti-HIV-1 antibody and anti-HIV-1 antibody binding molecule from the extended complex; and (d) determining the presence or concentration of the anti-HIV-1 antibody in the biological sample.Type: GrantFiled: December 23, 2010Date of Patent: May 13, 2014Assignee: The United States of America, as represented by the Secretary Department of Health and Human ServicesInventors: Hana Golding, Surender Khurana
-
Publication number: 20130143202Abstract: This invention relates to compositions and methods or the detection of immunodeficiency virus infection, especially immunodeficiency virus-1 (HIV-1) infection. The invention particularly concerns compositions and methods that may be used in HIV vaccine recipients whose sera may contain vaccine-generated anti-HIV-1 antibodies.Type: ApplicationFiled: December 23, 2010Publication date: June 6, 2013Applicant: The Government of the United States of America as represented by the Secretary, Department of HealthInventors: Hana Golding, Surender Khurana
-
Publication number: 20130137083Abstract: A combination of H5N1 influenza peptides that provide for H5N1 diagnosis with a high level of sensitivity and specificity is described.Type: ApplicationFiled: April 14, 2011Publication date: May 30, 2013Applicants: The Goverment of the United States of Americaas Represented by the Secretary of the Department of Health and Human ServicesInventors: Surender Khurana, Hana Golding
-
Publication number: 20120301504Abstract: The present invention includes influenza Hemagglutinin protein fragments that fold properly when expressed in bacteria.Type: ApplicationFiled: November 2, 2010Publication date: November 29, 2012Applicant: The Gov't of the USA As Represented by the Secreta ry of the Dept. of Health and Human Services, NatInventors: Surender Khurana, Hana Golding
-
Patent number: 8282926Abstract: The present invention relates, e.g., to an isolated peptide comprising a sequence of contiguous amino acids that is at least about 60% identical (e.g., at least about 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98% or 100% identical) to the sequence E-W-Q-K-E-G-L-V-T-L-W-L (SEQ ID NO:1), or an active variant of an isolated peptide comprising SEQ ID NO:1. Neutralizing antibodies generated by, or specific for, such peptides are also described, in particular antibodies which are specific for the HIV co-receptor, CCR5, and which inhibit infection of a host cell by HIV. Neutralizing single strand and complete human monoclonal antibodies against CCR5 are described. Methods of using such peptides or antibodies, for inhibiting infection by HIV, are also described.Type: GrantFiled: December 28, 2009Date of Patent: October 9, 2012Assignee: The United States of America, as Represented by the Secretary of the Department of Health and Human ServicesInventors: Hana Golding, Surender Khurana
-
Publication number: 20120196306Abstract: This invention relates to compositions and methods for the detection of immunodeficiency virus infection, especially immunodeficiency virus-1 (HIV-I) infection. The invention particularly concerns compositions and methods that may be used in HIV vaccine recipients whose sera may contain vaccine-generated anti-HIV-1 antibodies.Type: ApplicationFiled: May 21, 2010Publication date: August 2, 2012Inventors: Hana Golding, Surender Khurana
-
Publication number: 20110201035Abstract: This invention relates to compositions and methods or the detection of immunodeficiency virs infection, especially immunodeficiency virus-1 (HIV-1) infection. The invention particularly concerns compositions and methods that may be used in HIV vaccine recipients whose sera may contain vaccine-generated anti-HIV-1 antibodies.Type: ApplicationFiled: December 23, 2010Publication date: August 18, 2011Applicant: The United States of America as Represented by the Secretary of Health and Human Services, NIHInventors: Hana Golding, Surender Khurana
-
Publication number: 20110151436Abstract: This invention relates to compositions and methods or the detection of immunodeficiency virus infection, especially immunodeficiency virus-1 (HIV-1) infection. The invention particularly concerns compositions and methods that may be used in HIV vaccine recipients whose sera may contain vaccine-generated anti-HIV-1 antibodies.Type: ApplicationFiled: December 23, 2010Publication date: June 23, 2011Applicant: The Government of the United States of America as represented by the Secretary, Dept. of HealthInventors: Hana Golding, Surender Khurana